What Is Amylin? A Hormone for Blood Sugar and Appetite

Amylin is a 37-amino-acid peptide hormone produced by the same pancreatic beta cells that make insulin, and it is released alongside insulin every time you eat.¹ Its two main jobs are keeping blood sugar from spiking too high after meals and telling your brain you have had enough food. For decades, insulin dominated the conversation about metabolic hormones, but amylin is now at the center of some of the most promising obesity and diabetes research in a generation, including combination drugs that produce weight loss exceeding 20%.

How Amylin Gets Into Your Bloodstream

Amylin is stored inside the same tiny packets (secretory granules) as insulin within pancreatic beta cells.² When blood glucose rises after a meal, those granules fuse with the cell membrane and dump both hormones into the bloodstream at the same time. Studies using isolated rat pancreas tissue confirmed that the secretion pattern of amylin and insulin during glucose stimulation is identical, rising and falling in lockstep.³ This co-secretion matters because it means anything that damages beta cells, whether autoimmune destruction in type 1 diabetes or progressive burnout in type 2, depletes both hormones together.

Amylin circulates only briefly. The kidney is primarily responsible for breaking it down through enzymatic degradation, so blood levels peak soon after a meal and drop off quickly.⁴ This short lifespan is one reason why developing amylin-based drugs has been tricky: the native hormone disappears too fast to be useful as a medication, which led researchers to engineer longer-lasting synthetic versions.

Keeping Blood Sugar in Check After Meals

Insulin gets most of the credit for lowering blood sugar, but amylin handles a complementary piece of the puzzle. Rather than shuttling glucose into cells the way insulin does, amylin works upstream to slow the flood of glucose entering your blood in the first place. It does this through two main mechanisms.

The first is slowing gastric emptying. After you eat, food moves from the stomach into the small intestine, where nutrients are absorbed into the bloodstream. Amylin puts the brakes on that process, giving your body more time to manage each wave of incoming glucose. In a study of healthy humans given pramlintide (a synthetic amylin analog), the time it took for the stomach to empty half its contents rose from about 112 minutes on placebo to roughly 170 minutes or more with the drug.⁵ In people with type 1 diabetes, the delay was even more dramatic: the solid component of a meal had a median lag time of 150 minutes with pramlintide versus 44.5 minutes with placebo, and liquid emptying shifted from 7.5 minutes to 69 minutes.⁶ The effect is selective to the stomach; small bowel and colon transit are not significantly altered.

The second mechanism is suppressing glucagon. Glucagon is a hormone that tells the liver to release stored glucose. During a meal, you do not need additional glucose flooding in from the liver because you are getting plenty from the food itself. Amylin powerfully inhibits meal-related glucagon secretion, by roughly 70% in experimental models, helping ensure the liver stays quiet while digestion handles the glucose supply.⁷ Together, these two actions smooth out the postprandial glucose spike that is a hallmark of poorly controlled diabetes.⁸

How Amylin Tells Your Brain to Stop Eating

Beyond glucose management, amylin acts as a satiation signal. It does not just make you feel vaguely “less hungry” over the course of a day; it specifically promotes the sensation that a meal is over, reducing meal size rather than meal frequency.⁹

The primary brain region where amylin does this is the area postrema, a small structure in the hindbrain that lacks a complete blood-brain barrier. Because this barrier is thin there, circulating amylin released from the pancreas can reach neurons directly without needing a special transport system.¹⁰ Once area postrema neurons fire, the signal cascades through relay stations in the brainstem and up into the hypothalamus, the brain’s command center for energy balance.⁹ When this area is surgically destroyed in animal experiments, amylin’s ability to suppress food intake disappears.

The area postrema is rich in amylin receptors, but it is not the only site in the brain where amylin acts. Research has identified activity in other brain regions as well, including areas involved in reward-driven eating.¹¹ This is relevant because hunger is not purely about metabolic need; a lot of overeating is driven by the rewarding properties of food, and amylin appears to modulate that system too.

The Amylin Receptor System

Amylin does not bind to a single, simple receptor the way many hormones do. Instead, its receptors are built from two separate protein components that pair up: the calcitonin receptor and one of three different companion proteins called receptor activity-modifying proteins (RAMPs). This means there are three distinct amylin receptor subtypes, each formed by a different RAMP pairing.¹² The different subtypes are distributed in different tissues and produce slightly different cellular responses, which helps explain why amylin can have distinct effects in the brain, the pancreas, and elsewhere. This receptor complexity has also opened up a drug-design opportunity: researchers can try to build molecules that activate specific receptor combinations to fine-tune therapeutic effects.

Amylin belongs to a broader family of related peptides that includes calcitonin (a bone-regulating hormone) and CGRP (involved in migraine and blood vessel dilation). The shared evolutionary ancestry means these peptides have some overlapping receptor affinity, which is both an advantage and a complication for drug development.

What Happens When Amylin Is Missing

People with type 1 diabetes, whose immune system has destroyed most or all of their beta cells, have very low baseline amylin and essentially no amylin response when they eat.¹³ This means they are missing one of the body’s key brakes on postprandial glucose spikes and one of its meal-ending satiety signals, even when their insulin doses are carefully managed.

People with type 2 diabetes who have progressed to needing insulin also show a diminished amylin response after eating, likely proportional to how much beta-cell function they have lost.¹³ Earlier in the course of type 2 diabetes, when beta cells are still partially functional, amylin may actually be overproduced relative to normal, which creates its own set of problems.

The Dark Side of Amylin in Type 2 Diabetes

Human amylin has a troublesome property: it can misfold and clump together into toxic clusters called amyloid deposits. These deposits are found in the pancreatic islets of most people with type 2 diabetes and are thought to contribute to the progressive death of beta cells that characterizes the disease.¹⁴ The toxic forms of amylin damage cells by disrupting their outer membranes, stressing internal protein-processing machinery, and damaging mitochondria. The end result is a form of programmed cell death, with beta cells essentially self-destructing after contact with amylin fibrils.¹⁵

This creates a vicious cycle: insulin resistance drives beta cells to work harder, producing more insulin and more amylin. The excess amylin misfolds and aggregates, killing the very cells that made it. As beta cells die, insulin and amylin production both fall, worsening diabetes control.

An interesting evolutionary quirk sheds light on this problem. Rat and mouse amylin differ from human amylin by just six amino acid residues in the middle of the peptide, yet rodent amylin does not form fibrils and is not toxic. Researchers have shown that substituting even a single one of those human-specific residues into the rat version of the peptide can make it capable of forming clumps.¹⁶ This is why mice and rats do not naturally develop the islet amyloid deposits seen in human type 2 diabetes, and it is also why the synthetic amylin analog pramlintide was engineered with rat-like substitutions to avoid the aggregation problem.

Pramlintide, the First Amylin Drug

Pramlintide (brand name Symlin) is a synthetic version of amylin that was approved by the FDA for use alongside insulin in both type 1 and type 2 diabetes. It replicates amylin’s physiological actions without the tendency to clump into toxic fibrils. In clinical trials, adding pramlintide to insulin therapy improved postprandial glucose control and modestly reduced HbA1c, typically by about 0.2% to 0.7%, while also producing some weight loss, up to about 1.6 kilograms.¹⁷ Pramlintide reduced two-hour post-meal blood glucose by roughly 3.4 to 5 mmol/L, which is a meaningful improvement in day-to-day glucose swings even though fasting glucose was not significantly affected.

The weight loss side is worth noting because most insulin regimens cause weight gain, so a complementary therapy that nudges weight in the other direction is attractive. Some data also suggest favorable effects on lipids, including small reductions in LDL cholesterol in type 2 diabetes and triglycerides in type 1.¹⁸ The most common side effect is nausea, which tends to fade over time but is a meaningful barrier for some patients. Hypoglycemia is also a concern, since pramlintide slows glucose absorption while insulin is actively lowering blood sugar, creating a window where levels can dip too low if doses are not carefully coordinated.

Despite these benefits, pramlintide never became a blockbuster drug. It requires separate injections (it cannot be mixed with insulin in the same syringe), and the modest HbA1c reductions were not dramatic enough to drive widespread adoption. But pramlintide proved something important: replacing the missing amylin signal has real physiological value, especially for controlling after-meal glucose and appetite. That proof of concept paved the way for far more ambitious amylin-based therapies now in development.

Amylin and Leptin Working Together

One of the most intriguing findings in amylin research is that it appears to restore the body’s sensitivity to leptin, the “satiety hormone” produced by fat tissue. In obesity, leptin levels are high but the brain stops responding to the signal, a state called leptin resistance. This is one reason why people with obesity feel hungry despite having ample energy stores. In a landmark study, combining amylin and leptin treatment in diet-induced obese rats produced synergistic, fat-specific weight loss that neither hormone achieved alone. A clinical proof-of-concept trial in people with overweight or obesity found that co-treatment with pramlintide and recombinant leptin over 24 weeks led to about 12.7% mean weight loss, significantly more than either treatment on its own.¹⁹

Further work has identified at least one brain site where this cooperation occurs: the ventral tegmental area, a region associated with reward and motivation. When both amylin and leptin are delivered to this area in animal studies, the combination suppresses feeding and body weight more than either peptide alone, even at doses that are individually too low to have any effect.²⁰ Blocking amylin receptors in this region also blunted leptin’s effectiveness, suggesting amylin is not just an add-on but is required for leptin to work properly in that circuit.

There are limits. In extremely obese rats, the amylin-leptin synergy appeared to break down and was not restored even after calorie restriction brought weight partway down.²¹ Whether this ceiling applies equally in humans is still an open question, but it raises the possibility that amylin-based strategies have a window of effectiveness and that intervening earlier in the course of weight gain may matter.

Next-Generation Amylin Therapies and Cagrilintide

The biggest wave of excitement around amylin right now involves a new class of drugs designed to act on multiple receptors at once and last much longer in the body than pramlintide ever could. The most clinically advanced is cagrilintide, a long-acting amylin analog developed by Novo Nordisk. On its own, cagrilintide is a weekly injection that reduces appetite and body weight. But the real story is its combination with semaglutide (the active ingredient in Ozempic and Wegovy) in a product called CagriSema.

In a large trial, CagriSema produced an average body-weight reduction of about 20.4% from baseline over 68 weeks, compared with 3% for placebo.²² A meta-analysis of available trials found that CagriSema produced significantly greater weight loss than semaglutide alone, with a mean difference of about 7.5 percentage points.²³ The logic is straightforward: semaglutide targets GLP-1 receptors, and cagrilintide targets amylin receptors, and together they suppress appetite through two separate and complementary brain pathways.

Researchers are also developing dual amylin and calcitonin receptor agonists (DACRAs), which activate both receptor systems simultaneously. One experimental candidate has shown promise for once-weekly dosing in preclinical work, producing substantial weight loss and improved liver markers in obese rats.²⁴ Another DACRA candidate has been designed with an ultra-long half-life potentially suitable for dosing every two weeks and showed preferential fat reduction with minimal weight rebound after treatment ended in animal models.²⁵ These are still in early stages, but they suggest the amylin pathway has room for even more potent drugs than what is currently in trials.

Amylin and the Brain Beyond Appetite

An unexpected twist in amylin research involves Alzheimer’s disease. Just as amylin forms amyloid deposits in the pancreas, researchers have found amylin deposits in the brains of people with Alzheimer’s. More striking, amylin appears to interact directly with beta-amyloid, the protein at the center of Alzheimer’s pathology. In lab studies, amylin and beta-amyloid form mixed clumps (heterocomplexes) that are more toxic to neurons than either protein alone.²⁶

In brain tissue from people with familial Alzheimer’s disease, amylin levels correlated strongly with beta-amyloid levels. Staining revealed distinct amylin plaques, distinct beta-amyloid plaques, and mixed plaques containing both proteins in layered or interwoven arrangements.²⁷ The working hypothesis is that circulating amylin produced by the pancreas can cross into the brain and seed or accelerate the amyloid pathology associated with neurodegeneration. If this connection holds up, it would represent a remarkable link between metabolic disease and dementia, two conditions that epidemiologists have long suspected share underlying mechanisms.

This is still early-stage science, and it cuts both ways. Some researchers have explored whether amylin agonists could actually be neuroprotective, arguing that the normal, non-aggregated form of amylin has beneficial effects on brain neurons. The full picture remains unclear, but the existence of mixed amylin-amyloid plaques in human brains is a finding that has reshaped how some scientists think about both type 2 diabetes and Alzheimer’s disease.

Amylin’s Effects on Bone

Amylin is related to calcitonin, a hormone that inhibits bone breakdown, and early research explored whether amylin might have bone-building properties. In animal experiments, daily amylin injections increased bone volume in healthy rats and temporarily raised osteocalcin, a marker of bone formation. However, in diabetic animals with severe osteopenia (bone thinning), amylin was not able to reverse the damage, and the increase in the bone formation marker was temporary.²⁸ This suggests amylin may play a modest supporting role in bone turnover under normal conditions, but it cannot override the severe metabolic disruptions that diabetes causes in bone health. The bone angle has not been a major focus of drug development, but it adds to the picture of amylin as a hormone with surprisingly wide-ranging effects beyond glucose and appetite.